Physician profile
Michael S Hardee
NPI 1215922299
$5,772.78
in general payments reported to CMS, 2019-2025
28 companies · $1,161 in 2025
The $1,161 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $360 · 2021: $467 · 2022: $966 · 2023: $942 · 2024: $904 · 2025: $1,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,008.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,000.78 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $498.70 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $475.96 | 2022-2025 | Verquvo, Capvaxive |
| Amgen INC. | $431.81 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.71 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $304.55 | 2019-2025 | General - Therapies, Watchman Flx |
| Novo Nordisk INC | $289.76 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $274.84 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $271.09 | 2019-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $268.71 | 2019-2025 | Camzyos, Eliquis |
| Abiomed | $226.65 | 2024-2025 | Impella |
| Abbott Laboratories | $211.53 | 2022-2024 | Cardiomems |
| W. L. Gore & Associates, INC. | $192.42 | 2019-2021 | |
| Esperion Therapeutics, INC. | $140.51 | 2021-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $138.21 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $132.47 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $110.72 | 2019 | |
| Heartflow, INC. | $106.52 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $104.81 | 2023-2025 | Lifevest |
| Imperative Care, INC | $58.46 | 2025 | Symphony Catheter |
| Amarin Pharma, INC. | $42.79 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $37.87 | 2019 | |
| Gilead Sciences, INC. | $34.68 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $22.26 | 2024 | Uptravi, Opsumit |
| Lundbeck LLC | $21.97 | 2019 | |
| Medtronic Vascular, INC. | $21.29 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $18.21 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $16.50 | 2025 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hardee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.